It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pyrrolone-fused benzosuberene (PBS) compounds were semi-synthesized from α,β,γ-Himachalenes extracted from the essential oil of Cedrus deodara following amino-vinyl-bromide substituted benzosuberenes as intermediates. These PBSs compounds classified as an attractive source of therapeutics. The α-isoform of PI3K which is a pivotal modulator of PI3K/AKT/mTOR signaling pathway, responsible for neurological disorders like epilepsy, found as a potential target molecule against these 17 semi-synthesized PBS compounds using in silico ligand-based pharmacophore mapping and target screening. The compounds screened using binding affinities, ADMET properties, and toxicity that were accessed by in silico docking simulations and pharmacokinetics profiling. Ultimately two compounds viz., PBS-8 and PBS-9 were selected for further in vivo evaluation using a zebrafish (Danio rerio) model of pentylenetetrazol (PTZ)-induced clonic convulsions. Additionally, gene expression studies performed for the genes of the PI3K/AKT/mTOR pathway which further validated our results. In conclusion, these findings suggested that PBS-8 is a promising candidate that could bedeveloped as a potential antiepileptic.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Biotechnology division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Structural Bioinformatics Laboratory, Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X)
2 CSIR-Institute of Himalayan Bioresource Technology, Pharmacology and Toxicology Laboratory, Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X); CSIR-Institute of Himalayan Bioresource Technology, Academy of Scientific and Innovative Research (AcSIR), Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X)
3 CSIR-Institute of Himalayan Bioresource Technology, Pharmacology and Toxicology Laboratory, Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X)
4 CSIR-Institute of Himalayan Bioresource Technology, Natural Product Chemistry and Process Development, Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X); CSIR-Institute of Himalayan Bioresource Technology, Academy of Scientific and Innovative Research (AcSIR), Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X)
5 CSIR-Institute of Himalayan Bioresource Technology, Natural Product Chemistry and Process Development, Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X)
6 Biotechnology division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Structural Bioinformatics Laboratory, Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X); CSIR-Institute of Himalayan Bioresource Technology, Academy of Scientific and Innovative Research (AcSIR), Palampur, India (GRID:grid.417640.0) (ISNI:0000 0004 0500 553X)